Engineered extracellular vesicles (EVs): Promising diagnostic/therapeutic tools for pediatric high-grade glioma

Biomed Pharmacother. 2023 Jul:163:114630. doi: 10.1016/j.biopha.2023.114630. Epub 2023 Apr 23.


Diffuse intrinsic pontine glioma (DIPG) is a highly malignant brain tumor that mainly occurs in children with extremely low overall survival. Traditional therapeutic strategies, such as surgical resection and chemotherapy, are not feasible mostly due to the special location and highly diffused features. Radiotherapy turns out to be the standard treatment method but with limited benefits of overall survival. A broad search for novel and targeted therapies is in the progress of both preclinical investigations and clinical trials. Extracellular vesicles (EVs) emerged as a promising diagnostic and therapeutic candidate due to their distinct biocompatibility, excellent cargo-loading-delivery capacity, high biological barrier penetration efficiency, and ease of modification. The utilization of EVs in various diseases as biomarker diagnoses or therapeutic agents is revolutionizing modern medical research and practice. In this review, we will briefly talk about the research development of DIPG, and present a detailed description of EVs in medical applications, with a discussion on the application of engineered peptides on EVs. The possibility of applying EVs as a diagnostic tool and drug delivery system in DIPG is also discussed.

Keywords: Diffuse intrinsic pontine glioma (DIPG); Early diagnosis; Engineered modification; Extracellular vesicles (EVs); Targeted therapy.

Publication types

  • Review

MeSH terms

  • Brain Stem Neoplasms* / drug therapy
  • Brain Stem Neoplasms* / pathology
  • Cell Communication
  • Child
  • Drug Delivery Systems
  • Extracellular Vesicles* / pathology
  • Glioma* / drug therapy
  • Glioma* / therapy
  • Humans